Leukemia

Short-term growth potential of cryopreserved B chronic lymphocytic leukemia cells in suspension and in semisolid medium
TO THE EDITOR
There has been speculation, but limited data, concerning the inferior survival of malignant cells compared with benign stem cells during cryopreservation.
1,2 We have addressed this question by investigation of the proliferation and activation potential of freshly isolated and cryopreserved tumor cells from a cohort of 30 patients with typical B cell CLL and with blood lymphocyte counts above 30 × 10 9 /l. Peripheral blood mononuclear cells were isolated from heparinized (Noparin; Novo Nordik, Dagsvaerd, Denmark) blood samples by centrifugation over a Lymphoprep layer (Nycomed, Oslo, Norway) at a density of 1.077 g/ml as described elsewhere. 3, 4 Density gradient centrifugation yields, without other purification steps, were good (range 29-92%; mean 61.7%; s.d. 16.2%, n = 36). This information is necessary for interpretation of the results. 5 The proportion of monocytes plus polyclonal T-and B-lymphocytes was 1-13%, indicating that 87-99% of the isolated cells represented the leukemic population. Immunophenotyping was performed by flow cytometry (FACSCalibur, Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) using commercial mouse monoclonal antibodies and respective immunoglobulin isotype controls.
Diagnosis and staging were based on standard clinical, morphological and immunophenotyping criteria. All patients had a CD19 + /CD5 + immunophenotype, and mature CLL, CLL/mix or CLL/PL morphology. 6 Most patients had chromosomal aberrations but none indicating chronic lymphoid leukemias other than typical CLL. 6 For cryopreservation, the cells were suspended in 50% fetal calf serum (Gibco BRL, Paisley, UK), 10% dimethylsulfoxide (RiedeldeHaen, Seelze, Germany) and 40% culture medium (Hepes-RPMI 1640; 20 mM Hepes, ICN Biochemicals, Costa Mesa, CA, USA) at a density of 2 × 10 7 cells/ml. The cells were allowed to cool slowly from +20°C to −80°C overnight and thereafter transferred to liquid nitrogen for various time periods. Immediately after melting, the viability of cryopreserved cells was assessed by trypan blue dye exclusion. The mean viability was 95.7% (range 87-98%; s.d. 2.7%; n = 56).
We used in vitro assays to evaluate the growth and activation potential of cryopreserved cells in B cell chronic CLL. An optimal mitogen combination (OMC) for each patient was selected from 13 different combinations of four mitogens: interleukin-2 (IL-2 10 U/ml); Staphylococcus aureus Cowan 1 (SAC, 0.005%), 12-O-tetradecanoylphorbol 13-acetate (TPA1, 1 ng/ml and TPA10, 10 ng/ml) and human recombinant tumor necrosis factor alpha (TNF␣, 10 ng/ml). The combinations were: IL-2, SAC, SAC + IL-2, TPA10, TPA10 + IL-2, TPA1, TPA1 + IL-2, TNF␣, TNF␣ + IL-2, TNF␣ + TPA10, TNF␣ + TPA1, TNF␣ + TPA10 + IL-2, TNF␣ + TPA1 + IL-2. as recently described. 3, 4 We have previously shown that all tested mitogens and their combinations induce a powerful activation and proliferation response when assessed with freshly isolated cells in 4-day cultures (see above). We confirmed here that every mitogen and mitogen combination induced a significant increase in leukemia cell proliferation when tested by using the Wilcoxon matched pair test (P Ͻ 0.00001, n = 30). Thirty analyses of fresh cells and 53 analyses of cryopreserved cells were performed in suspension cultures: (1) proliferation analysis after OMC stimulation in 4-day cultures, by using thymidine incorporation, and (2) activation analysis by using leucine incorporation or total protein synthesis as an end point. 3, 4 In all cases, proliferation and activation 
Figure 1
Proliferation (a) and activation (b) of leukemic cells induced by OMCs in 4-day cultures: fresh (time 0) and as clustered to two storage periods in liquid nitrogen. The activation index was determined as the ratio: (dpm incorporation in an OMC-stimulated culture)/(dpm incorporation in a corresponding control culture). N on the top refers to the number of analyses per column (+ s.e.m.).
Figure 2
Growth of cryopreserved leukemia cells in semisolid medium. Cells from 10 patients were allowed to grow for 3, 7 and 14 days in the presence of an optimal mitogen combination. The clusters were assigned to three size categories and counted microscopi- Leukemia rescence analysis was performed in a manner similar to that described in the preceding paragraph. Two-color fluorescence in situ hybridization was performed to detect chromosome 12 trisomy and Rb gene deletions, essentially as described previously. 6, 7 The clusters were not real colonies formed by one single tumor cell. Nevertheless, this strategy allowed us to further illustrate the growth potential of cryopreserved leukemia cells (Figure 2) . The results demonstrated significant increases in the numbers of average-sized clusters between days 3 and 7 and in the numbers of large clusters between days 3 and 7, as well as between days 3 and 14.
All clusters were of leukemic B cell phenotype, with less than 5% of the cells being of T-phenotype (10 cases analyzed; results not shown). Furthermore, the clusters contained the appropriate clonal genomic aberration in three cases investigated by FISH: one case with trisomy 12 and two cases with Rb −/+ loss of heterozygosity (results not shown).
Proliferation of individual cells in methylcellulose cultures was further evaluated by 60-min labeling of S-phase cells with 5-bromodeoxyuridine. The labeled cells were visualized by UV microscopy after indirect immunostaining with mouse monoclonal anti-5BrdUrd followed by FITC-conjugated sheep anti-mouse antibody. Most of the leukemic clusters contained FITC-labeled S-phase cells and up to 20-25% of the cells were in the S-phase (Figure 3) . Hence, 5-bromodeoxyuridine labeling of leukemic cells unequivocally demonstrated the growth potential of cryopreserved CLL cells.
In most reports the growth potential of leukemic cells has been investigated using freshly isolated cells. Reported investigations concern occasional patients with acute leukemia, but no results of systematic studies concerning variable and long storage periods are available.
Chronic lymphocytic leukemia is an interesting candidate for autologous stem cell transplantation. 8 The present work clearly demonstrated that CLL cells retain their viability for long periods in liquid nitrogen, when assessed using growth and activation potential as indicators. Hence, cryopreservation is not an adequate method to purge stem cell preparations before autologous transplantation.
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Laboratory A 54-year-old man was admitted to Osaka City University Hospital because of left neck tumors. Based on histological findings for a biopsied lymph node, ALCL was diagnosed. Surface marker analysis revealed that malignant cells were positive for CD25 (77.3%) and CD30 (40.8%), but negative for CD2 (1.1%), CD3 (7.6%), CD4 (15.4%), CD5 (10%), and CD8 (1.3%). On immunohistochemical studies, lymphoma cells were CD45 (LCA) (±), CD20 (L-26) (−), CD45RO (UCHL-1) (+), CD30 (Ki-1) (+), and epithelial membrane antigen (EMA) (+). Chimeric ALK-NPM gene was not detected by polymerase chain reaction (PCR). No atypical cells were present in peripheral blood or bone marrow. Serum LDH level was high (919 IU/l) and serum Ca levels were within normal limits (4.5 mEq/l). Serum antibody against HTLV-I was positive by a routine particle agglutination method (titer of 4096) and Western blot analysis. Southern blot analysis was performed using DNA extracted from the biopsied lymph node. Monoclonal integration of HTLV-I proviral DNA was detected using ScaI fragment (8. Southern blot analysis of HTLV-I proviral DNA, T cell receptor gene, and EBV genome. Genomic DNA was extracted from biopsied lymph node and was digested with EcoRI (E), PstI (P), EcoRV (R), BamHI (B), and HindIII (H) restriction endonucleases. The digested DNA (5 g) was electrophoresed through 0.8% agarose gels and transferred to nylon membranes. The blots were hybridized to probes (a) ScaI fragment of HTLV-I proviral DNA, (b) TCR C␤1 DNA, (c) BamHI-EcoRI fragment of EBV terminal repeated sequences) labeled with 32 P by random primer method. 1: ATL cell line, 2: placenta, 3: the presented case.
